Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of a Comprehensive Package Based on Multimarker Blood-based Point-of-care Testing on Antibiotic Prescribing for Acute Respiratory Tract Infections at Village Clinics in China

11. november 2026 oppdatert av: Xiaoxv Yin, PhD, Huazhong University of Science and Technology

This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China.

Studieoversikt

Status

Har ikke rekruttert ennå

Intervensjon / Behandling

Detaljert beskrivelse

This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China. We will conduct the trial over six months in 80 village clinics across 10 townships in Xiantao and Jingmen, Hubei Province (with 5 townships in Xiantao and 5 in Jingmen). Village clinics will be randomly assigned in a 1:1 ratio to either the intervention or control group, stratified by city and township. A comprehensive intervention package based on multimarker blood-based POCT will be implemented in 40 village clinics within the intervention group. In addition to equipping these clinics with POCT devices, we will provide systematic guidance through a combination of centralised training sessions and the distribution of training manuals. The training will focus on the standardised operation of POCT and clinical pathways to guide antibiotic prescriptions for the treatment of ARIs based on test results. We will provide patient education through leaflets, primarily aimed at helping rural patients understand how multimarker blood-based POCT can aid in their diagnosis and treatment, thereby improving patient acceptance. The control group will undergo diagnosis and treatment in accordance with routine care procedures, without any intervention.

Studietype

Intervensjonell

Registrering (Antatt)

70000

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Hubei
      • Jingmen, Hubei, Kina, 448000
        • 40 Village Clinics
        • Ta kontakt med:
        • Ta kontakt med:
      • Xiantao, Hubei, Kina, 433000
        • 40 Village Clinics
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Eligibility criteria for clusters. Village clinics will be eligible if they have not previously participated in a POCT-guided antibiotic prescribing programme, record more than 2,000 outpatient visits annually, manage an average of at least 10 patients with ARIs per week, and have licensed prescribers. Eligibility will be verified using prescription records from the preceding year obtained from the information management departments of the local health authorities.

Eligibility criteria for participants. The target population comprises patients of all ages who either (1) have been diagnosed by village doctors with an ARI, including upper or lower respiratory tract infections; or (2) present with at least one acute respiratory symptom or sign, such as cough, sore throat, rhinitis (nasal congestion, sneezing, or rhinorrhoea), wheezing, or abnormal findings on auscultation. Patients diagnosed with non-respiratory conditions and those whom village doctors consider require referral to a higher-level healthcare facility based on their clinical presentation will be excluded.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Control group

The control group will not have any intervention, as the control (usual care)

Eksperimentell: Intervention group

All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs.

All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs.

Each intervention clinic will receive a concise, easy-to-follow decision flowchart summarising the prespecified thresholds for selected CBC parameters, CRP, and SAA.

Following randomisation, all village doctors in the intervention group will receive standardised centralised training.

The research team will also provide each village clinic in the intervention group with a guidance manual on appropriate antibiotic use for ARIs supported by combined CBC, CRP, and SAA POCT.

Plain-language, non-technical information leaflets will be distributed at all village clinics in the intervention group.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The primary outcome will be a binary indicator of whether at least one antibiotic is prescribed by the village doctor during an eligible index consultation for an ARI.
Tidsramme: The 6-month intervention

An index consultation is defined as an ARI-related consultation by a patient who has not had any recorded ARI consultations at the same village clinic in the preceding 14 days. This measure aims to capture the overall effect of the POCT-supported multicomponent intervention on antibiotic prescribing decisions for ARIs. Since most ARIs are viral and self-limiting, a lower prescribing proportion-provided that patient recovery and safety are not compromised-would indicate more selective use of antibiotics by village doctors. This endpoint is particularly suitable for research in village clinics in China because prescriptions are now routinely recorded electronically rather than solely on paper. These digital records enable standardised data extraction and auditing, thereby supporting the completeness and traceability of outcome ascertainment.

The 6-month intervention

Sekundære resultatmål

Resultatmål
Tidsramme
The proportion of eligible index consultations in which two or more antibiotics are prescribed
Tidsramme: The 6-month intervention
The 6-month intervention
The proportion in which at least one antibiotic is administered intravenously
Tidsramme: The 6-month intervention
The 6-month intervention
The proportion in which at least one traditional Chinese medicine is prescribed
Tidsramme: The 6-month intervention
The 6-month intervention
The medication cost per eligible index consultation
Tidsramme: The 6-month intervention
The 6-month intervention
The total cost per eligible index consultation
Tidsramme: The 6-month intervention
The 6-month intervention

Andre resultatmål

Resultatmål
Tidsramme
The proportion of patients who initiate any additional antibiotic during the 14 days following an eligible index consultation for an ARI will be assessed in a randomly selected subsample
Tidsramme: The 6-month intervention
The 6-month intervention
The principal safety outcome will be the proportion of patients admitted to any hospital within the corresponding study city for an ARI or sepsis within 30 days after the index consultation.
Tidsramme: The 6-month intervention
The 6-month intervention
In the randomly selected patient subsample, we will also assess time to recovery from ARI symptoms through the 14-day telephone follow-up.
Tidsramme: From the index consultation to the end of treatment at 2 weeks
From the index consultation to the end of treatment at 2 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

15. desember 2026

Primær fullføring (Antatt)

15. juni 2027

Studiet fullført (Antatt)

15. juli 2027

Datoer for studieregistrering

Først innsendt

11. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • HuazhongU20261111

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere